Monoclonal antibody and protein therapeutic formulations for subcutaneous delivery: high-concentration, low-volume vs. low-concentration, high-volume.

Desai, M; Kundu, A; Hageman, M; Lou, H; Boisvert, D

Desai, M; Kundu, A; Hageman, M; Lou, H; Boisvert, D.

Afiliación

Desai M; Medical Affairs, Enable Injections, Inc, Cincinnati, OH, USA.
Kundu A; Manufacturing Sciences, Takeda Pharmaceuticals, Brooklyn Park, MN, USA.
Hageman M; Department of Pharmaceutical Chemistry, The University of Kansas, Lawrence, KS, USA.
Lou H; Biopharmaceutical Innovation & Optimization Center, The University of Kansas, Lawrence, KS, USA.
Boisvert D; Independent Chemistry Manufacturing & Controls (CMC) Consultant, El Cerrito, CA, USA.

MAbs ; 15(1): 2285277, 2023.

Article en En | MEDLINE | ID: mdl-38013454

Asunto(s)

Productos Biológicos; Neoplasias; Humanos; Anticuerpos Monoclonales/uso terapéutico; Inyecciones Subcutáneas; Neoplasias/tratamiento farmacológico; Productos Biológicos/uso terapéutico

Palabras clave

Monoclonal antibodies; high-concentration; high-volume; protein therapeutics; subcutaneous

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Productos Biológicos / Neoplasias Idioma: En Revista: MAbs Asunto de la revista: ALERGIA E IMUNOLOGIA Año: 2023 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google